A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.
The presence of some fungal species in tumors predicts—and may even help drive—worse cancer outcomes, according to a study from Weill Cornell Medicine and Duke University researchers.
A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led by scientists at Weill Cornell Medicine, NewYork-Presbyterian and Heidelberg University Hospital.
Seven Weill Cornell Medicine faculty members leading multi-institutional research teams were awarded grants from The Starr Foundation's 12th Starr Cancer Consortium Grant Competition to fund their innovative cancer research projects.
Eight Weill Cornell Medicine faculty members have been selected for the fifth round of the Daedalus Fund for Innovation awards, a pioneering institutional program that helps advance promising applied and translational research projects and emerging technologies that have commercial potential.
A rare inherited gene mutation predisposes people to developing a form of blood cancer called multiple myeloma, according to a new study by a multicenter research team led by Weill Cornell Medicine scientists.
